Involvement of aquaglyceroporins in energy metabolism in health and disease

Giuseppe Calamita a, Christine Delporte b, *

a Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari “Aldo Moro”, Bari, Italy
b Laboratory of Pathophysiological and Nutritional Biochemistry, Université Libre de Bruxelles, Brussels, Belgium

ABSTRACT

Aquaglyceroporins are a group of the aquaporin (AQP) family of transmembrane water channels. While AQPs facilitate the passage of water, small solutes, and gases across biological membranes, aquaglyceroporins allow passage of water, glycerol, urea and some other solutes. Thanks to their glycerol permeability, aquaglyceroporins are involved in energy homeostasis. This review provides an overview of what is currently known concerning the functional implication and control of aquaglyceroporins in tissues involved in energy metabolism, i.e. liver, adipose tissue and endocrine pancreas. The expression, role and (dys)regulation of aquaglyceroporins in disorders affecting energy metabolism, and the potential relevance of aquaglyceroporins as drug targets to treat the alterations of the energy balance is also addressed.

© 2021 Published by Elsevier B.V.

Keywords:
Aquaporins
Energy metabolism
Adipose tissue
Endocrine pancreas
Liver
Clinical disorders
Drug targets

Contents

1. Introduction .......................................................................................................................... 21
2. Structure and characteristics of human aquaglyceroporins .................................................. 21
   2.1. AQP3 ............................................................................................................................... 21
   2.2. AQP7 ............................................................................................................................... 22
   2.3. AQP9 ............................................................................................................................... 22
   2.4. AQP10 ............................................................................................................................ 22
3. Hepatic aquaglyceroporins .................................................................................................. 22
   3.1. Expression in human and rodents .................................................................................. 23
   3.2. Function ........................................................................................................................ 23
       3.2.1. AQP9 ..................................................................................................................... 23
       3.2.2. AQP3, AQP7 and AQP10 .................................................................................... 23
   3.3. Regulation ..................................................................................................................... 23
   3.4. Metabolic disorders ....................................................................................................... 24
4. Adipocyte aquaglyceroporins .............................................................................................. 24
   4.1. Expression .................................................................................................................... 24
       4.1.1. Human expression .................................................................................................. 24
       4.1.2. Mouse expression .................................................................................................. 25
       4.1.3. Rat expression ........................................................................................................ 25
   4.2. Regulation ..................................................................................................................... 25
       4.2.1. Trafficking mechanism .......................................................................................... 25
       4.2.2. Transcriptional mechanism .................................................................................... 25

* Corresponding author.
E-mail address: christine.delporte@ulb.be (C. Delporte).

https://doi.org/10.1016/j.biochi.2021.03.001
0300-9084/© 2021 Published by Elsevier B.V.
1. Introduction

AQPs are a family of transmembrane protein channels featuring six transmembrane helices surrounding a narrow water-permeable channel in which water flows in a single file [1]. In biological membranes, AQPs assemble in tetramers, creating a fifth narrow channel through the center that was suggested to be permeable to CO₂ [2]. Thirteen mammalian AQPs have been identified and named AQP0 to AQP12 [3,4]. AQPs structure features an internal tandem repeat of three transmembrane segments and a pair of highly conserved signature asparagine-proline-aspartate (NPA) motifs forming a pore and defining the permeability selectivity [3,5,6].

According to their sequences homologies and permeability, mammalian aquaporins are grossly subdivided into three main groups: (i) orthodox aquaporins (AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, and AQP8), homologues that were initially thought to only allow the passage of water; (ii) aquaglyceroporins (AQP3, AQP7, AQP9, and AQP10), homologues allowing the passage of water, glycerol and some small solutes, and (iii) unorthodox aquaporins (or superaquaporins; AQP11 and AQP12), two AQPs characterized by their divergent evolutionary pathway, and whose channel selectivity is still matter of debate. However, this classification is not exhaustive since additional solutes can pass through, sometimes even more efficiently than the molecules that were initially considered to be the only substrates. AQP3, AQP6, AQP8, and AQP9 are also permeated by ammonia and are also termed ammoniaoporins [7]. AQP1, AQP3, AQP5, AQP8, AQP9, and AQP11 also allow the passage of hydrogen peroxide, and are therefore called peroxiporins [8–11]. Moreover, AQP7 and AQP9 have been reported to move arsenite [12], AQP6 to be permeable to nitrate and halide ions [13,14], AQP1 to be a gated ion channel [15], and AQP9 to facilitate monocarboxylate passage [16]. Some AQP channels have also been reported to facilitate transmembrane movement of gases of biological relevance such as NO, CO₂ or O₂ [17–19]. The biological significance of the passage of these other molecules remains largely unknown and object of debate.

In light of their expression in many mammalian tissues and organs, AQPs ensure diverse roles in healthy and pathological conditions [3,4,20]. Among the functions ascribed to aquaglyceroporins in the various organs in which they are expressed, important roles are played in liver, adipose tissue and endocrine pancreas where they participate to energy metabolism. By facilitating the uptake/release of glycerol, substrate used for the synthesis of triacylglycerols (TAG) and for gluconeogenesis depending on the states of energy balance, aquaglyceroporins have important implications in the control of fat accumulation in adipose tissue and liver, in glucose homeostasis and oxidative stress [21–25]. In addition, in endocrine pancreas, AQP7-mediated glycerol uptake plays a role in β-cell insulin secretion [26–28].

This review provides the current state of knowledge concerning the involvement of aquaglyceroporins in energy metabolism by focusing on their expression, role and regulation in liver, adipose tissue and endocrine pancreas. In addition, the review provides an overview of the role of aquaglyceroporins in disorders affecting energy metabolism, the consequences of disorders on aquaglyceroporins expression and function, and the main pharmacological tools available to target aquaglyceroporins.

2. Structure and characteristics of human aquaglyceroporins

The overall AQP structure revealed by multiple studies confirmed the existence of the initially suggested “hourglass model” [29]. In accordance with this model, each AQP monomer forms a pore composed of six transmembrane helices connected by five loops (A to E loops; two intracellular and three extracellular). At the vicinity of the extracellular channel mouth, the so-called aromatic/arginine selectivity filter (ar/R SF) featuring the most conserved part of the pore controls the passage of molecules based on their size [30]. An arginine residue, highly conserved among AQPs and charged positively, is located in a typically aromatic sidechain environment excluding the passage of protons while accommodating the passage of glycerol and urea [31,32]. Underneath, two highly conserved NPA motifs present in the B and E loops and half-helices contribute to the formation of the pore center and ensure the exclusion of charged solutes [33–37]. Aquaglyceroporins contain two additional peptide spans located within the second and third extracellular loops as compared to orthodox AQPs, and two relatively conserved NPA motifs in which the presence of an aspartic acid (D) in the second NPA motif expands the pore to allow the passage of larger solutes such as glycerol [38,39]. Aquaglyceroporins features an ar/R SF region wider that other AQPs, allowing the passage of larger solutes [40]. Recent studies have confirmed that AQPs pore size determines exclusion properties but not solute selectivity [41]. Despite groundbreaking studies on AQPs structure and better structural insights into AQPs selectivity [1], structural information concerning aquaglyceroporins remains quite limited mainly in reason of to the absence of crystallized proteins.

2.1. AQP3

To our knowledge, the human AQP3 protein crystal structure has not been obtained. However, structural studies have been
conducted using a homology model of tetrameric AQP3 built based on the crystal structure of the glycerol uptake facilitator protein (GlpF) from Escherichia coli [38,42–44]. *Xenopus laevis* oocytes and cells expressing AQP3 and atomic modelling and large-scale simulations have established the permeability of AQP3 to water, glycerol, urea and H$_2$O$_2$ [45–52]. AQP3 permeability to urea has been the subject of some controversies [53], but recent data indicate the lack of urea permeability of human AQP3 expressed in HEK293 cells [41]. A more recent study revealed the mechanisms of AQP3 water and glycerol permeation at the atomistic level using metadynamics approaches [35]. Both single-file water and glycerol permeate human AQP3 in a bidirectional way in the absence of osmotic gradient, with free energy for permeation smaller for water than for glycerol [35]. The bidirectional water flux is disrupted consequentially to glycerol molecules permeating the pore [35]. Although ar/R SF being the narrowest part of the pore, the NPA represents an energy barrier for both water and glycerol permeation [35]. Water and glycerol make hydrogen bonds with amino acids located within the ar/R SF (Y212, A213 and R218), the NPA (N83, N215) and the cytoplasmic pocket (H81, E191) [35]. Human AQP3 point mutation Y212A affected glycerol but not urea permeability, while combined point mutations G203H/Y212A abolished both glycerol and urea permeabilities, and point mutation G203H reduced protein expression [41].

### 2.2. AQP7

The AQP7 sequence has the particularity to contain conserved NPA motifs modified to NAA (in positions 94–96) and NPS (in positions 226–228) for the first and second motifs, respectively [54,55]. *Xenopus laevis* oocytes or cells expressing rat, mouse or human AQP7 permeate water, as well as glycerol, urea and H$_2$O$_2$ [50,56,57]. Compared to orthodox AQPs, AQP7 displays lower permeability in cell-based assays [58,59] but similar water permeability in proteopolysomesome assay performed using a glycerol-free set up [60], or reduced water permeability in the presence of glycerol using molecular dynamics simulations [61]. The AQP7 structure has been elucidated in recent works using X-ray crystallography and molecular-dynamics stimulations [57,61]. Human AQP7 displays a pore of around 3 Å of diameter at the selectivity filter [61] comprising amino acid residues F74, G222, V223 and R229 [57]. AQP7 tetramers contain two monomers with three molecules of glycerol and two monomers with two molecules of glycerol within the pore [57]. The AQP7 structure is quite flexible as its F74 residue undergoes rapid conformational changes from a closed to an opens state, allowing the passage of glycerol without strong orientation restriction [57], with a partly rotating movement that may serve to break hydrogen bonds and allow its movement along the channel pore [61]. Water molecules pass along glycerol molecules to allow glycerol permeation as both molecules compete for hydrogen-bonding sites in the pore [62]. This competition mechanism along with the rotation of glycerol might facilitate glycerol release [61]. Studies of heterologous expression of human AQP7 in yeast displayed similar glycerol permeability for this aquaglyceroporins at pH values ranging between 6 and 8 [58,59]. However, at acidic pH (pH 5), both glycerol [58,63] and water permeabilities were reduced with no change in pore size [63]. The reduction of glycerol permeability of AQP7 at acidic pH was suggested to be due to the protonation of Y135 and H165 rather than a true gating mechanism. Furthermore, the presence of some pH-sensitive amino acids at the monomer-monomer interface of the tetramer suggests that the decreased permeability of AQP7 results from the cooperativity between AQP7’s monomers [63].

### 2.3. AQP9

Human AQP9 has been shown to be permeable to water as well as to glycerol, urea and H$_2$O$_2$ [12,41,50,56,64,65]. Despite the lack of structure for human AQP9, two-dimensional crystallization of rat AQP9 indicates that monomers form a tetrameric structure [39]. A homology model of tetrameric AQP9 built based on the crystal structure of the bacterial glycerol uptake facilitator protein (GlpF) reveals the conserved pore residues (G80, H82, N84, N216, R219 in rat AQP9) located at the faces presenting groups involved in formation of hydrogen bonds, predominantly in the center of the channel, while the residues conserved only among all aquaglyceroporins (I60, V68, L172, I199, I200, G208, G212, A214, M215) located within helices 2 and 4 and loop E all sit in the center of the channel on its hydrophobic portion [39]. In addition, residues forming portion of the channel and conserved among all AQP9 homologues (F64, G81, M91, V176, F180, L209, C213) fall into the hydrophobic face of the pore and are located within helices 2 and 4, loops B and E, and pore helix HB [39]. Proton-exclusion mechanism likely regulates solute permeation in AQP9 similarly to other AQPs as the constricted region of the pore in all AQP9 is conserved similarly to AQPs [39]. Large solute permeation across AQP9 may require solute-induced change in the pore region [39].

### 2.4. AQP10

Human AQP10 expressed in HEK293 cells exhibit some permeability to glycerol and urea [41], while permeability to H$_2$O$_2$ remains to be determined. The relatively recent crystal structure determination of AQP10 unveiled its unique characteristic to be stimulated by pH reduction as it displays a pH-dependent glycerol-specific gating at the intracellular interface, in contrast to other AQPs [60]. In-depth unveiling of the aquaglyceroporins structure contributes to better understanding of diseases and provides additional perspectives for the design of new therapeutic tools.

### 3. Hepatic aquaglyceroporins

Once imported into hepatocytes, glycerol is phosphorylated leading to glycerol-3-phosphate (G3P), an essential metabolite in fat accumulation being required for TAG synthesis and gluconeogenesis occurring during fasting or exercise thereby being of critical importance for glucose homeostasis [66]. Glycerol derived from the diet, lipolysis or reabsorbed at the proximal renal tubes contributes to blood free glycerol levels. Furthermore, cell glycerol content results from the conversion of G3P arising from glycolysis, or the conversion of pyruvate, lactate and alanine through a pathway called *glyceroneogenesis* that occurs in the white and brown adipose tissues, and in the liver to sustain TAG synthesis, especially when TAG metabolism is augmented [66].

Liver exerts a central function in glycerol metabolism, considering its predominant (70–90%) contribution to the whole-body glycerol metabolism [66]. The use of hepatic glycerol implies sexual dimorphism. Indeed, glucose metabolism and lipid metabolism predominate in men and women, respectively. Under physiological conditions, glycerol metabolism is gender-dependent, especially during hypoglycemia, fasting or exercise [67] (see section 3.1). The
liver express all four aquaglyceroporins with difference in term of levels and cellular and subcellular localization. Among these aquaglyceroporins, AQP9 is the most abundantly expressed. Table 1 summarizes some characteristics of liver aquaglyceroporins.

### 3.1. Expression in human and rodents

AQP9 is located at the sinusoidal plasma membrane of rodent and human hepatocytes [71,78]. In rat liver, the AQP9 expression is stronger in the pericentrallobular region of the hepatic lobule than in the periportal area [73,79]. Males exhibit higher hepatic expression of AQP9 than females both in rodents and human [22,80,81].

At a lesser extent compared to AQP9, human hepatocytes also express the other three aquaglyceroporins, AQP3, AQP7, and AQP10 [68,69]. Hepatic transcript levels of AQP3 are higher in women than men whereas no sexual dimorphism in the liver transcriptional levels has been observed regarding AQP7 and AQP10 [69]. AQP3 is also reported in human hepatic stellate cells (HSC) [82] and in human Kupffer cells [68].

### 3.2. Function

#### 3.2.1. AQP9

AQP9 is the main pathway through which glycerol is imported from portal blood [72,83], a not insignificant aspect given that the glycerol passage through the membrane limits the rate of glycerol use by the liver [84]. Once imported into the cell, glycerol is promptly converted into G3P by the glycerol kinase. G3P is of particular importance as substrate for de novo synthesis of glucose (gluconeogenesis) during short term starvation [85] and for TAG synthesis during feeding [75]. As expected, liver glycerol permeability is reduced in Aqp9-depleted (Aqp9−/−) mice, while plasma glycerol and TAG levels are increased [73,83]. Likely due to its broad selectivity, additional roles for AQP9 in the liver have been suggested in primary bile formation [74,86] and hepatic extrusion of catabolic urea [76]. In liver, AQP9 also mediates excretion of arsenic [77]. AQP9 has also been immunodetected in the cholangiocytes lining mouse intrahepatic bile ducts [68], but the related physiological meaning is still elusive.

#### 3.2.2. AQP3, AQP7 and AQP10

The functional role of AQP3, AQP7, and AQP10 in human hepatocytes, if any, remains to be proven. A role for AQP3 in lipogenesis of quiescent HSC was suggested after finding that its expression decreases during cell activation [70,82]. In human Kupffer cells, AQP3 has been reported to be involved processes occurring during liver regeneration liver diseases (such as cell repopulation, migration, cytokine secretion) [68]. Overall, the roles of AQP3, AQP7, and AQP10 in liver remain to be assessed by additional studies.

### 3.3. Regulation

In rodents, hepatocyte Aqp9 is transcriptionally downregulated by insulin [87], explaining why rodent models of type 1 diabetes [88] and subjects with insulin resistance [69] show increased hepatic levels of AQP9 as well as the diminished glycemia (−10−40%) of obese diabetic leptin-receptor-deficient db/db mice lacking Aqp9 [73]. The hepatic glucose metabolism has been modeled as multiple steps integrating the hepatocyte uptake and handling of glycerol in the glucose-insulin axis as a function of the glycolysis stores, plasma glycerol and glycerol permeability to hepatic AQP9 protein levels [89]. The model can assess the contribution of AQP9 to murine liver glycerol permeability over time during the course metabolic status [89]. Hepatocyte AQP9 is also regulated transcriptionally by leptin [22,75]. Unexpectedly, leptin and insulin regulate AQP9 transcription differently in rodents and humans [22,90]. In the human hepatocellular carcinoma cell line HepG2, insulin and leptin were seen to increase and decrease the expression of AQP9. This was reported to occur through the activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling cascade [75] and AMP protein kinase (AMPK), via forkhead box a2 (Fox a2) [91,92]. However, the question regarding the insulin and leptin regulation of hepatocyte AQP9 in human remains open and needs further investigation since no AQP9 expression was found in a recent work using HepG2 cells [78]. Fasting-induced increase of AQP9 in rat liver was found to be 2.6 times higher in males than females, in line with the concurrent observation that during fasting, male rats showed unmodified plasma glycerol level whereas the plasma glycerol levels were increased in the female counterpart [93], and with the liver glycerol permeability that was higher in males. Ovariectomized rats behave similarly to male rats. These in vivo findings and

---

**Table 1**

<table>
<thead>
<tr>
<th>Aquaglyceroporin Permeability</th>
<th>Cell type</th>
<th>Subcellular location</th>
<th>Suggested role</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AQP3</strong></td>
<td>Water, glycerol, hydrogen peroxide, ammonia, urea</td>
<td>Kupffer cells (h)</td>
<td>Undefined</td>
<td>Repopulation of Kupffer cells in liver regeneration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatocytes (h)</td>
<td>Undefined</td>
<td>Uptake of glycerol (?)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stellate cells (h)</td>
<td>Undefined</td>
<td>Cell activation</td>
</tr>
<tr>
<td><strong>AQP7</strong></td>
<td>Water, glycerol</td>
<td>Hepatocytes (h, IC; others? m)</td>
<td>Uptake of glycerol (?)</td>
<td>TAG synthesis; uptake of glycerol (?)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cholangiocytes (h)</td>
<td>APM</td>
<td>TAG synthesis; uptake of glycerol (?)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endothelial cells (h)</td>
<td>APM</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>AQP9</strong></td>
<td>Water, glycerol and other polyols, hydrogen peroxide, lactate, ammonia, arsenite, urea and some other uncharged solutes</td>
<td>Hepatocytes (h, m, r)</td>
<td>BLPM</td>
<td>Uptake of portal glycerol for gluconeogenesis and TAG synthesis; import of water from portal blood (bile formation); urea extrusion; arsenic detoxification; liver regeneration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cholangiocytes (h)</td>
<td>Undefined</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>AQP10</strong></td>
<td>Water, glycerol, urea (?)</td>
<td>Hepatocytes (h)</td>
<td>Undefined</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

APM, apical plasma membrane; BLPM, basolateral plasma membrane; h, human; IC, intracellular; m, mouse.
the in vitro data obtained on hepatocytes treated with estrogen infer that sexual dimorphism account for differential AQP9 regulation during fasting and concomitant higher plasma glycerol levels in female [93]. The peroxisome proliferator-activated receptor α (PPARα) downregulated AQP9 in rat male perportal hepatocytes [94].

Scarc is the knowledge about the regulation of AQP3, AQP7 and AQP10 in the healthy liver. In HepG2 hepatocytes, AQP3 and AQP7 were found to be upregulated and downregulated, respectively, by leptin [75].

3.4. Metabolic disorders

Due to their role in mediating the membrane passage of glycerol, liver aquaglyceroporins, especially AQP9, are of pathophysiological relevance in liver metabolic disorders (Table 2). Seen their peroxiporin activity, roles for AQP9 and AQP3 cannot be ruled out in disorders of the redox balance and inflammatory diseases.

Non-alcoholic fatty liver disease (NAFLD) is a complex disease characterized by ectopic accumulation of TAG in hepatocytes which varies from simple fatty liver to non-alcoholic steatohepatitis (NASH) and to cirrhosis [100]. NAFLD is frequently associated with the metabolic syndrome often accompanied by obesity and diabetes mellitus with insulin resistance. Involvement of hepatocyte AQP9 has been reported in human NAFLD as well as in studies using rodent or cell models of NAFLD [69,95–97,99]. The decreased AQP9 expression seen in obesity and/or diabetes could contribute to decreasing the substrate availability for de novo TAG synthesis and limiting fat overaccumulation in hepatocytes and to reducing gluconeogenesis to hamper the aggravation of hyperglycemia [22,69,97]. Despite comparable levels of liver AQP9 expression, obese women diverged from obese men by their lower liver glycerol permeability [69]. This may reflect the lower incidence of insulin resistance and NAFLD in women than men. However, no relationship was found between hepatic AQP9 expression and extent of liver steatosis in patients with morbid obesity [101]. Also, Aqp9 knockdown in db/db mice did not change the hepatic fat content [102]. These results are not consistent with a study using a cell model of NAFLD where silencing of AQP9 prevented or alleviated the degree of intracellular steatosis [103]. A work with male cell model of NAFLD where silencing of AQP9 prevented or alleviated the expression of both AQP3 and AQP9 [114] or could only detect the lower incidence of in- US influence of AQP9 expression in human HepG2 cells only [93], or also to adipocytes [115]. The expression of AQP3 [75], AQP7 [75] and AQP10 [115] in human adipocytes has not reached a shared consensus. Indeed, some studies could not detect the expression of both AQP3 and AQP9 [114] or could only detect AQP9 [78]. Worth noting that AQP11, an unorthodox homologue of AQP9, is expressed in human fat cells.

<table>
<thead>
<tr>
<th>Aquaglyceroporin</th>
<th>Cell type</th>
<th>Pathophysiological involvement</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>AQP3</td>
<td>Kupffer cells (h)</td>
<td>Cell migration and secretion of pro-inflammatory cytokines</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>Hepatocytes (h)</td>
<td>Insulin resistance (?)</td>
<td>[75]</td>
</tr>
<tr>
<td></td>
<td>Stellate cells (h)</td>
<td>NAFLD, NASH, fibrosis and cancer (PNPLA3 I148 M variant)</td>
<td>[70]</td>
</tr>
<tr>
<td>AQP7</td>
<td>Hepatocytes (h, m)</td>
<td>Insulin resistance</td>
<td>[75]</td>
</tr>
<tr>
<td></td>
<td>Cholangiocytes (h)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endothelial cells (h)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>AQP9</td>
<td>Hepatocytes (h, m, r)</td>
<td>NAFLD; NASH; obesity; T2D; hepatocellular carcinoma</td>
<td>[22,69,95–99]</td>
</tr>
<tr>
<td></td>
<td>Cholangiocytes (h)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>AQP10</td>
<td>Hepatocytes (h)</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>
4.2.1. Trafﬁcking mechanism

Protein trafﬁcking plays a key role in the regulation of aquaglyceroporins function. Indeed, aquaglyceroporins localized in subcellular vesicles translocated to the plasma membrane (to ensure transcellular glycerol passage) upon stimulation with intracellular signaling pathway [57,115,122,130,131].

cAMP-inducing hormones or agents induced translocation of AQP3, AQP7 and AQP9 from intracellular vesicles to the plasma membrane, but had no effect on AQP9 localized at the membrane [75,115]. Upon insulin stimulation of 3T3-L1 adipocytes, AQP3 and AQP7 tended to appear more prominently surrounding the lipid droplets and while AQP9 localization increased at the plasma membrane [75].

4.2.2. Transcriptional mechanism

The transcription of aquaglyceroporins is regulated by hormones (i.e., insulin, catecholamines, steroids) and proinflammatory mediators (i.e., TNF-α and lipopolysaccharides) [75,113,118,125,132]. Both human and mouse Aqp7 transcription is upregulated by peroxisome proliferator-activated receptor gamma (PPARγ) [118,133] and modulated by the Kupffer-like factor 15 (KLF-15), a transcription factor playing a role in lipogenesis [134].

4.2.3. Epigenetic mechanism

DNA methylation at CpG dinucleotides, one of the epigenetic mechanisms by which cells modulate gene expression, can regulate Aqp7 expression [135]. The presence of high proportion of methylated CpG-sites in Aqp7 gene promoter correlated with a down-regulation of the gene expression [136]. While some mRNAs can interact with some aquaglyceroporins, their role in aquaglyceroporins regulation in adipose tissue remains to be investigated [137,138]. Further analyses will be required to shed more light on the role of epigenetic mechanisms in aquaglyceroporins regulation in adipose tissue.

4.2.4. pH-induced mechanism

So far, all aquaglyceroporins, with the exception of AQP9, have been reported to be regulated by a pH-dependent gating mechanism.

Indeed, rat AQP3 glycerol passage was signiﬁcantly lower at pH 6.0 and completely abolished at pH below 5.7 [47,139], while another study showed it was unmodiﬁed at pH in the range 6–7 [140]. Extracellular pH reduction also decreased AQP3 water permeability, involving H53, Y124 and H154 residues [141]. The investigation of the molecular mechanisms responsible for pH-dependent AQP3 gating disclosed important structural features [139].

Human AQP7 displayed similar glycerol permeability at both high and low pH (pH range 6–8) [58,59]. In contrast, at pH 5, that may not be quite meaningful physiologically, glycerol [58,63] and water permeabilities are reduced, but not the pore size [63]. The reduction in glycerol permeability of AQP7 may be consecutive to the protonation of Y135 and H165 rather than a true gating mechanism. In addition, the protonated residues may be responsible for a cooperativity change between the AQP7 monomers within the tetramer that alters permeability [63].

Human AQP10 displays a pH-dependent glycerol-speciﬁc gating in both intracellular interface, in contrast to other AQPs [60]. Upon double protonation induced by low pH exposure, the amino acid R94 to allow the passage of glycerol [60].

4.2.5. Phosphorylation mechanism

Current knowledge about phosphorylation of aquaglyceroporins is very limited. Indeed, only human AQP3 was shown to be phosphorylated upon CAMP-induced hormone on T514 and this phosphorylation paralleled the increase in AQP3 trafﬁcking to the plasma membrane in an intestinal epithelial cell line [142]. It remains to be determined whether other aquaglyceroporins can undergo phosphorylation upon hormone stimulation in parallel with their trafﬁcking.

4.3. Function

Adipose tissue ensures the synthesis and storage of TAG during feeding, and their degradation and release during fasting [66,143]. These processes require transmembrane passage of glycerol through aquaglyceroporins. As such, aquaglyceroporins participate to energy metabolism. The function of aquaglyceroporins has been deciphered using aquaglyceroporin knockout animals, adipocyte differentiation models, and adipose tissue samples. The role played by AQP7 in adipocytic glycerol release has been unveiled using differentiated adipocytes [119] and Aqp7 knockout mice [120,144,145]. In addition, AQP3 could contribute to cell glycerol exit during lipolysis, and AQP9 could allow cell glycerol entrance during TAG synthesis [75].

The involvement of AQP9 in adipocyte glycerol uptake relies on various facts. AQP9 expression located at the plasma membrane of mouse 3T3-L1 adipocytes, and was higher upon insulin stimulation [75]. Insulin increased AQP9, in addition to AQP3 and AQP7, in human omental adipocytes, while leptin decreased AQP9, as well as AQP7, expression though the PI3K/Akt/mTOR pathway [75]. Due to the low activity of the adipocyte glycerol kinase during lipogenesis, glycerol uptake is likely limited. Using selective AQPs inhibitors, the relative contribution of aquaglyceroporins to the glycerol permeability of 3T3-L1 adipocytes were estimated to 68% for AQP3, 3% for AQP7 and 12% for AQP9
However, the contribution of AQP7 to glycerol permeability was estimated to 45% using RNA interference [144]. Plausible explanations may account for the observed variability in AQP7 contribution to adipocytic glycerol permeability. Indeed, incomplete effects of the inhibitors and possible off target effects of RNA interference could respectively underestimate or overestimate AQP7 contribution to adipocytic glycerol permeability [126].

Lower expression and lack of regulation of aquaglyceroporins in beige adipocytes versus white adipocytes differentiated from 3T3-L1 cells are in agreement with the commitment of beige adipocytes to metabolize fat to produce heat instead of performing TAG synthesis and degradation that involves glycerol passage [128].

Adipocytes undergo rapid intracellular acidification or alkalization in response to lipolytic agents or insulin, respectively [146–150]. Therefore, adipocyte intracellular pH modifications are likely involved in pH-induced gating mechanisms of aquaglyceroporins. Under fasting, lipolysis is known to induce intracellular pH acidification that does not drop below pH 6.5 [60,146]. Therefore, under these conditions, AQP3 and AQP7 would retain a glycerol permeability superior to 50% [63], while AQP10 would display high glycerol permeability [50], both contributing to glycerol efflux. In contrast, under feeding, insulin-induced intracellular pH alkalinization would trigger high AQP3- and AQP7-mediated glycerol permeability contributing to glycerol influx, but low AQP10-mediated glycerol permeability. While it remains to be determined whether AQP9 also undergoes a pH-dependent gating mechanism, AQP9 may be still involved in glycerol import upon feeding (see above).

AQP11 is expressed in the endoplasmic reticulum and its expression is upregulated during human adipocyte differentiation and lipolysis [117]. Physiologically, AQP11 allows glycerol passage for TAG synthesis in nascent lipid droplets in the endoplasmic reticulum [117].

Based on current understanding of the role of aquaglyceroporins in adipocyte energy metabolism, we proposed an updated working model whereby mainly AQP3, AQP7 and AQP10 would be involved in glycerol exit during lipolysis, while mainly AQP3, AQP7 and AQP9 would be involved in glycerol entrance during lipogenesis [126]. However, the contribution of each aquaglyceroporins to glycerol metabolism in adipose tissue remains to be fully deciphered, possibly with the use of mice carrying the conditional knockout of one or more aquaglyceroporin gene(s) or using isoform-specific and potent inhibitors.

### 4.4. Metabolic disorders

A brief overview on the role of adipocytic aquaglyceroporins in metabolic disorders will be provided, due to available extensive review on the subjects [24,90,107–111]. Table 3 summarizes the involvement of aquaglyceroporins in metabolic disorders.

The capacity of Aqp7 knockout mice to develop or not an obesity phenotype may arise from their genetic background [144,145,161]. The site of AQP7 expression, exclusively in endothelial cells [93,121] or in endothelial cells and adipocytes [115,122], could account for the susceptibility to develop obesity [162]. In an animal model of metabolic syndrome (i.e. rats depleted in n3-polyunsaturated fatty acids (PUFA)), the level of AQP7 protein, but not mRNA, was decreased in adipose tissue (PUFA depletion is likely responsible for the absence of PPARY activation that is then uncapable to trans-activate AQP7 [118] and thereby glycerol passage [158]. Lipopolysaccharide, known to play an important role in obesity [163], decreased glycerol permeability and increased TAG content in 3T3-L1 adipocytes, without modification of AQP7 protein expression [126].

Animals fed an obesogenic high fat diet displayed various modulations of Aqp3, Aqp7 and Aqp9 mRNA levels [81,129,164–166]. Data variability may arise from differences in animal species (rat, mouse), adipose tissue investigated, duration of obesogenic diet, animal genetic background and assay conditions.

DNA methylation of the human AQP7 gene has been associated with adiposity. Indeed, Aqp7 gene methylation was significantly increased in four adiposity phenotypes including android fat mass, android:gonid fat ratio and trunk:limb fat ratio [135]. Furthermore, high proportion of methylated CpG-sites detected in Aqp7 gene promoter correlated with a downregulation of the gene expression in human hypertrophic white adipose tissue that is generally associated with insulin resistance and type 2 diabetes [136]. However, Aqp7 gene methylation could not be detected in rats fed with high fat diet to create an obesogenic environment [167]. Nevertheless, Aqp7 downregulation, achieved using interfering RNA knockdown of Aqp7, stimulated lipid storage in mesenchymal stem cells subsequently differentiated into adipocytes [136], consistently with the role of AQP7 to ensure the passage of glycerol, used as a substrate and product of lipid metabolism [119].

The human AQP7 gene is located in a chromosomal region linked to type 2 diabetes (T2D) [133,160] and metabolic syndrome [159]. Therefore, several studies have assessed AQP7 expression in patients with obesity, T2D and metabolic syndrome. However, no correlation has been observed between AQP7 gene mutations and obesity or T2D [113]. Adipose tissue from obese subjects presents either higher or lower AQP7 expression, according to the studies [75,101,151–157]. Clinical features of obese subjects, as well as their gender, may account for these apparent contradictory data [22]. Lower KLF-15 expression that could reduce AQP7 expression may account for insulin resistance in adipose tissue [134].

AQP11 has recently been shown to act an endoplasmic reticulum-resident protein involved in endoplasmic reticulum stress induced by lipotoxicity and inflammation in human obesity [117]. The peroxiporin activity of AQP11 appears to lessen the endoplasmic reticulum stress caused by lipotoxicity and inflammation [117].

Table 3

<table>
<thead>
<tr>
<th>Aquaglyceroporin</th>
<th>Cell type</th>
<th>Pathophysiological involvement</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>AQP7</td>
<td>Adipocytes (h, m, r)</td>
<td>Obesity</td>
<td>[75,101,114,135,144,145,151–157]</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells (h, m)</td>
<td>Metabolic syndrome</td>
<td>[158,159]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insulin resistance</td>
<td>[136]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T2D</td>
<td>[133,160]</td>
</tr>
<tr>
<td>AQP3</td>
<td>Adipocytes (h, m, r)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>AQP9</td>
<td>Adipocytes (h, m, r)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>AQP10</td>
<td>Adipocytes (h)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>AQP11</td>
<td>Adipocytes (h, m)</td>
<td>Obesity</td>
<td>[117]</td>
</tr>
</tbody>
</table>

h, human; m, mouse; r, rat; T2D, type 2 diabetes mellitus.
Despite numerous studies aiming at evaluating the role of aquaglyceroporins in energy metabolism disorders, additional studies will be required to deepen our knowledge on the subject.

5. Pancreatic endocrine aquaglyceroporins

5.1. Expression

Endocrine cell clustered into islets of Langerhans and single endocrine cells scattered among the pancreas constitutes the endocrine pancreas. The islets of Langerhans are clusters of few to several thousand cells of five main well-characterized endocrine cell types: β-cells producing insulin; α-cells producing glucagon; δ-cells producing growth hormone-inhibiting hormone (GH/HR - also termed somatostatin); γ-cells producing pancreatic polypeptide (PP); and ε-cells producing gherlin [168,169]. Among human and rodent islets of Langerhans, the endocrine cell types vary in their proportions [170–172] and localization (core or rim of islets) [170,171]. From a physiological point of view, both insulin and glucagon play major roles in the control of energy metabolism in post-prandial and in pre-prandial states, respectively. Indeed, it is well known that insulin, secreted in response to increased glycaemia, and glucagon, secreted in response to decreased glycaemia, are anabolic and catabolic hormones, respectively, controlling the mobilization and storage of carbohydrates, lipids and amino acids.

Current state of knowledge reports the expression of Aqp7 in rodent (rat and mouse) β-cells [26–28,128,161]. In mouse and rat β-cells, AQP3 mRNA expression has not been detected [161,173]. While AQP9 mRNA expression has not been detected in mouse β-cells, its expression was detectable in 10% of rat pancreatic samples analyzed [173].

The possible presence of additional aquaglyceroporins in β-cells, as well as aquaglyceroporins expression in other islet endocrine cell types require further investigations.

5.2. Regulation

In response to triggered lipolysis in adipocytes, increased blood glycerol levels will induce local β-cells intracellular glycerol concentration increase and subsequent β-cell activation. In addition, insulin or other agents downregulating AQP7 expression will likely increase the intracellular β-cell glycerol concentration and induce cell activation [113,118]. Recent data partly corroborated this hypothesis as Aqp7 overexpression decreased insulin release in rat RIN-m5F β-cells [128]. However, reduced Aqp7 expression had no impact on insulin release [128]. In addition, tumor necrosis factor-alpha (TNFα) and LPS, respectively decreasing or increasing Aqp7 mRNA expression, both decreased insulin release in rat RIN-m5F β-cells [128]. This apparent contradiction might be related to the measurement of Aqp7 mRNA levels rather than AQP7 protein expression levels or cell glycerol permeability under TNFα and LPS treatment, to the condition of insulin secretion (in the absence or presence of glycerol), or to the effects of cytokines released upon TNFα and LPS stimulation. As such, additional experiments will help shedding light on this issue.

5.3. Function

The role of AQP7 in β-cell intracellular glycerol content and both insulin production and secretion has been deciphered using Aqp7-knockout (KO) mice [27,121,144,161], ex vivo β-cells [26] and BRIN-DB11 β-cell line [28]. A reduction in β-cell number, size and insulin content was documented in Aqp7-KO mice as compared to wild type (WT) mice [161]. In addition, Aqp7-KO mice displayed higher intra-islet levels of both glycerol and TAG, higher glycerol kinase activity, but no glycerol efflux in response to forskolin [161]. Depending on the genetic background of Aqp7-KO mice models used, the animals displayed various phenotypes characterized by either normal glycaemia with undetermined insulinemia [121], normal glycaemia with hyperinsulinemia [161], or hyperglycaemia and hyperinsulinemia [144]. The various phenotypes of Aqp7-KO mice models could result from combined interactions between AQP7 and other gene products. This hypothesis warrants additional experiments to decipher the AQ79 interacome. Fig. 1 resumes the phenotype of Aqp7-KO mice.

The current model of insulin secretion is based on the existence of sequential mechanisms including: glucose entry through glucose transporter type 2 (GLUT2), glucose metabolism, intracellular ATP level increase, ATP-sensitive potassium channels inhibition, membrane depolarization, voltage-dependent calcium channels opening, intracellular calcium concentration increase, and insulin-containing granules release [174]. Glucose entry in β-cell leads to cell swelling [175], and subsequent activation of volume-regulated anion (VRAC) channel inducing regulatory volume decrease, cell depolarization, voltage-dependent calcium channel activation, intracellular calcium level increase, and insulin secretion [175,176]. Upon exposure of rat β-cells or rat BRIN-DB 11 cells to extracellular isosmotic addition of glycerol, cells encounter cell swelling and subsequent here above-mentioned mechanisms leading to insulin release [Fig. 2] [26,28,178]. Both glycerol entry and metabolism are likely accounting for the observed β-cells activation [26]. Extracellular isosmotic addition of glycerol, extracellular hypotonicity or increased α-glucose level induced increased insulin release in β-cells from Aqp7-KO mice as compared to WT mice [27]. The role played by glycerol and AQP7 in insulin secretion corroborate the correlation between glucose-induced insulin secretion and β-cell lipolysis [179–181]. Consequently, AQP7 allows glycerol passage, and modulate the insulin secretion pathway at a distal downstream site [27].

5.4. Metabolic disorders

Aquéaglyceroporins are described to be of pathophysiological relevance in metabolic disorders affecting the pancreas (Table 4). Indeed, in the context of type 2 diabetes, both insulin resistance and insulinemia may also induce an intracellular glycerol concentration increase in β-cells [178]. In obesity, β-cell activation of TNFα receptor and TLR4 may play a role in type 2 diabetes by modulating Aqp7 expression. Indeed, TNFα and LPS, inducing cytokine production/release, respectively decreased or increased Aqp7 mRNA expression in rat RIN-m5F β-cells [128]. Opposite to lean rats, pancreas from obese rats have by higher AQP7 mRNA and protein levels. In addition, Aqp7 mRNA levels are negatively correlated with total ghrelin and glucagon-like peptide 1 (GLP-1) concentrations [173]. Restored pancreatic AQP7 expression and improved pancreatic β-cell function have been observed in obese rats with sleeve gastrectomy [173]. AQP7 could become a the target for therapeutic intervention in metabolic diseases, and in particular obesity and diabetes [112].

Overall, additional studies are necessary to further deciphering the function of AQP7 in β-cells and metabolic diseases, assess the possible presence and role of other aquaglyceroporins, as well as determine the expression of aquaglyceroporins in other islet endocrine cell types.

6. Main pharmacological tools targeting aquaglyceroporins

Reflecting the strong interest in the subject, the full characterization of what it is already known and search for new and more selective and potent inhibitors of aquaglyceroporins and, more
Fig. 1. Characteristics of Aqp7-KO mice. ATGL: adipose triglyceride lipase; GK: glycerol kinase; TAG, triacylglycerols.

Fig. 2. AQP7 function in β-cell insulin secretion. Following glycerol entry through AQP7 in β-cells, multiple steps lead to insulin secretion.

Table 4
Suggested pathophysiological roles of pancreas aquaglyceroporins.

<table>
<thead>
<tr>
<th>Aquaglyceroporin</th>
<th>Cell type</th>
<th>Pathophysiological involvement</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>AQP7</td>
<td>β-cells (m,r)</td>
<td>Obesity</td>
<td>[112,128,173]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diabetes</td>
<td>[161]</td>
</tr>
<tr>
<td>AQP9</td>
<td>β-cells (r*)</td>
<td>unknown</td>
<td>[173]</td>
</tr>
</tbody>
</table>

m: mouse; r: rat.
* Present in about 10% of samples.
generally, of all aquaporin groups is currently very intense [24,182,183]. For the purpose of this review, only aquaglyceroporin inhibitors are considered.

The Cu²⁺ and Ni²⁺ ions were reported to bind to extracellular loop sites of human AQP3 [141,184]. In the related studies, inhibitor potency was not fully clarified as it resulted to vary depending on the employed buffer. Indeed, Cu²⁺ inhibited AQP3 water and glycerol permeability with an IC₅₀ ranging from ~5 μM in bicarbonate buffer to the millimolar range in Tricine or HEPES buffers, and had no effect of AQP7 permeabilities in bicarbonate buffer [141,184]. It is worth mentioning that the normal human plasma Cu²⁺ levels range from 1 to 15 μM. Nickel chloride (1 mM) reduced AQP3 water permeability by about 60% in human bronchial epithelium cells overexpressing the protein, compared to sham-transfected cells. The inhibitory effect exerted by Ni²⁺ ions likely occurs on the extracellular loop residues Trp-128, Ser-152, and His-241 [141].

The Hg²⁺ ion binds to a pore-lining cysteine residue found on most AQPs including AQP3, AQP9 and AQP10 (but not AQP7) and blocks the channel. However, mercury and its compounds are toxic due to their non-specificity causing off-target effects the reason why it is used only in cell-based studies.

Some gold(III) compounds have been reported to block the molecular passage operated by aquaglyceroporin channels. The AuIII-based compound [Au(phen)Cl₂]Cl (phen = 1,10-phenanthroline; Auphen) was proved to inhibit AQP3 [185]. Biophysical and computational analyses suggested binding of Auphen to the side chain of a cysteine residue (Cys40) located nearby of the AQP3 pore constriction [43]. Auphen was also reported to inhibit mouse and human AQP7 through direct binding to a methionine (Met47) at the pore mouth facing the intracellular compartment [186]. AQP3 has been shown to be blocked by Aubipy ([Au(bipy)Cl]⁺ (bipy = 2,2’-bipyridine), another gold coordination compounds [187–189].

Phloretin, a bioactive chalcone with various health benefits [184], is a proven blocker of the facilitated passage of glycerol and urea across membranes [49,190]. Although it does not allow to distinguish among the various aquaglyceroporin phloretin is largely employed in the biophysical characterization of the aquaglyceroporin-mediated passage of glycerol and urea in basic research [76,83]. Small molecule inhibitors of AQP9 were identified after screening a commercially available library of drug-like molecules [72,191]. One of the identified inhibitors, the heterocyclic compound HTS12386, inhibited the AQP9-mediated glycerol permeation with an IC₅₀ of ~2 μM. The limited solubility in water (~25 μM in 1% DMSO-containing aqueous solution) makes HTS12386 not suitable for in vivo applications. However, HTS12386 is revealing a good blocker of AQP9 for characterizing the biophysical properties and function in vitro not to mention the possibility of identifying structural derivatives with a more potent inhibitory action on AQP9 and/or with higher water solubility for potential drug development.

Novel inhibitors of AQP3 and AQP7 have recently been identified [50]. The heterocyclic compounds DFP00173 and Z433927330 blocked the glycerol permeability of human erythrocytes with an IC₅₀ of ~0.2 μM and ~0.6 μM, respectively. In CHO cells, compound DFP00173 specifically blocked mouse AQP3 with an IC₅₀ of ~0.1 μM but not AQP7 and AQP9, while Z433927330 inhibited mouse AQP7 with an IC₅₀ of ~0.2 μM but not AQP3 and AQP9. The IC₅₀ values for Z433927330 for mouse AQP3 and AQP9 were ~0.7 μM and ~1.1 μM, respectively. In the same study by Sonntag and coworkers, the previously identified AQP9 inhibitor RJ03176 [72] was found to block aquaglyceroporin H₂O₂ permeability. Molecular docking suggested binding of Z43927330, DFP00173 and RJ03176 to amino acid residues at the cytoplasmic entrance of the AQP9 pore.

7. Conclusions and outlook

Adipose, liver and endocrine pancreas aquaglyceroporins play a significant role in the function these organs exert in metabolic and energy homeostasis. In the light of their physiological functions, aquaglyceroporins play relevant roles in diseases accompanied by metabolic and energy imbalances. Modulation of aquaglyceroporins by some bioactive phytocompounds is found to prevent or improve some chronic metabolic disease. New and more sustainable aquaglyceroporin inhibitors are being discovered offering promise for novel therapeutic strategies where targeting aquaglyceroporins may help managing obesity, diabetes and NAFLD/NASH. Additional and important achievements on the role and regulation of aquaglyceroporins in health and disease as well as their translational value are anticipated.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This study was supported by grants from the Fonds David and Alice Van Buuren, Jaumotte Demoulin Foundation, de Meurs François Foundation and Defay Fund (Université Libre de Bruxelles) to C.D. Financial support to G.C. from Italian “Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale 2017” (PRIN2017; grant # 2017J92TM5) is gratefully acknowledged. The Authors thank Bahija Jellouli for her secretarial help.

References


S.P. Mukherjee, C. Mukherjee, Metabolic activation of adipocytes by insulin
G. Calamita and C. Delporte Biochimie 188 (2021) 20
H. Meisner, K. Tenney, PH as an indicator of free fatty acid release from
D. Rudman, P.W. Shank, Observations on the production of hydrogen ions
R. Mourelatou, E. Kostopoulou, A.P. Rojas-Gil, I. Kehagias, D. Linos,
L. Portois, Y. Zhang, J. Perret, K. Louchami, N. Gaspard, E. Hupkens, N. Bolaky,
S. Prudente, E. Flex, E. Morini, F. Turchi, D. Capponi, S. De Cosmo, V. Tassi,
N.E. Boutagy, R.P. McMillan, M.I. Frisard, M.W. Hulver, Metabolic endotox-
M.T. Skowronski, A. Skowronska, A. Rojek, M.K. Oklinski, S. Nielsen, Pro-
membrane, lipolytic agonists, and insulin, Proc. Natl. Acad. Sci. Unit. States
A.S. Verkman, Progressive adipocyte hypertrophy in aquaporin-7-deficient

A.S. Verkman, M.O. Anderson, M.C. Papadopoulos, Aquaporins: important
J.C. Henquin, Regulation of insulin secretion: a matter of phase control and
H. Mulder, S. Yang, M.S. Winzell, C. Holm, B. Ahren, Inhibition of lipase activity

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

G. Uriarte, L. Paternain, F.I. Milagro, J.A. Martínez, J. Campion, Shifting to a

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the


V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

G. Uriarte, L. Paternain, F.I. Milagro, J.A. Martínez, J. Campion, Shifting to a

H. Mulder, S. Yang, M.S. Winzell, C. Holm, B. Ahren, Inhibition of lipase activity

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

V. Graziani, A. Marrone, N. Re, C. Coletti, J.A. Platts, A. Casini, A multi-level

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the

M. Zelenina, S. Tritto, A.A. Bondar, S. Zelenin, A. Aperia, Copper inhibits the